CN1311830C - Cefadroxil oral disintegrant tablet, and its prepn. method - Google Patents
Cefadroxil oral disintegrant tablet, and its prepn. method Download PDFInfo
- Publication number
- CN1311830C CN1311830C CNB2004100075451A CN200410007545A CN1311830C CN 1311830 C CN1311830 C CN 1311830C CN B2004100075451 A CNB2004100075451 A CN B2004100075451A CN 200410007545 A CN200410007545 A CN 200410007545A CN 1311830 C CN1311830 C CN 1311830C
- Authority
- CN
- China
- Prior art keywords
- cefadroxil
- oral cavity
- aspartame
- disintegration tablet
- mentholum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960004841 cefadroxil Drugs 0.000 title claims abstract description 56
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title description 4
- 239000007884 disintegrant Substances 0.000 title description 2
- 210000000214 mouth Anatomy 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 19
- 108010011485 Aspartame Proteins 0.000 claims description 18
- 239000000605 aspartame Substances 0.000 claims description 18
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 18
- 235000010357 aspartame Nutrition 0.000 claims description 18
- 229960003438 aspartame Drugs 0.000 claims description 18
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 18
- 239000000796 flavoring agent Substances 0.000 claims description 17
- 235000019634 flavors Nutrition 0.000 claims description 17
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims description 15
- 206010056474 Erythrosis Diseases 0.000 claims description 15
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 15
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 12
- 238000007689 inspection Methods 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 8
- 239000011265 semifinished product Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 235000015165 citric acid Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 229960004106 citric acid Drugs 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 229960001407 sodium bicarbonate Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 239000000945 filler Substances 0.000 abstract description 10
- 239000000080 wetting agent Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000314 lubricant Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- -1 cefadroxil anhydride Chemical class 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 235000005976 Citrus sinensis Nutrition 0.000 description 3
- 240000002319 Citrus sinensis Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- GHQFLMULNSGOAR-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;sodium Chemical compound [Na].OC(=O)C(O)C(O)C(O)=O GHQFLMULNSGOAR-UHFFFAOYSA-N 0.000 description 1
- HTRWTTRXUXPGEY-UHFFFAOYSA-L C(C=CC(=O)[O-])(=O)[O-].[Na+].NCC(=O)O.[Na+] Chemical compound C(C=CC(=O)[O-])(=O)[O-].[Na+].NCC(=O)O.[Na+] HTRWTTRXUXPGEY-UHFFFAOYSA-L 0.000 description 1
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000000770 erythrosyl group Chemical group C1([C@H](O)[C@H](O)CO1)* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- XBGWNOZEENJJQG-UHFFFAOYSA-L magnesium hydrogen carbonate octadecanoate Chemical compound [Mg++].OC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XBGWNOZEENJJQG-UHFFFAOYSA-L 0.000 description 1
- WDSFYHBVGUZHAM-UHFFFAOYSA-K magnesium sodium octadecanoate carbonate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Mg+2].C([O-])([O-])=O.[Na+] WDSFYHBVGUZHAM-UHFFFAOYSA-K 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a cefadroxil oral disintegration tablet and a preparation method thereof. The cefadroxil oral disintegration tablet comprises an effective amount of cefadroxil and medicinal excipient capable of quickly disintegrating and releasing medicines in an oral cavity, wherein the medicinal excipient can be a water soluble filling agent, a disintegrating agent, a lubricating agent, a wetting agent or an adhesive. The cefadroxil oral disintegration tablet has the advantages of quick disintegration, quick effect, little residue in the intestinal tract, full absorption, low side effect, convenient medication and good taste.
Description
Technical field
The present invention relates to a kind of cefadroxil oral cavity disintegration tablet and preparation method thereof.
Technical background
Cefadroxil is a kind of broad-spectrum antibiotic, to golden Portugal bacterium and various streptococcus and the equal tool height of anaerobic cocci antibacterial activity.Also very strong to some enterobacteria antibacterial action.Its bactericidal action mechanism is similar with other 'beta '-lactam antibiotic, is to realize by the formation that suppresses bacteria cell wall.This medicine has advantages such as has a broad antifungal spectrum, bactericidal action are strong, long half time.Clinical respiratory tract due to the sensitive organism, urinary tract, skin, the soft tissue infection of being used for.Its untoward reaction is few and light, based on gastrointestinal reaction.
The cefadroxil structural formula is as follows:
The dosage form of the cefadroxil of clinical practice at present has tablet, capsule, granule, and these peroral dosage forms all need use water delivery service, and taking medicine for dysphagia or the inconvenient patient of water intaking has certain difficulty; Though granule is the dosage form that aims at the child patient design, owing to most children can not oneself take after mixing it with water, and it is also very inconvenient to take granule when school or kindergarten, so these dosage forms can't satisfy all patients' medication needs fully.
Summary of the invention
The object of the present invention is to provide a kind of novel form that can overcome the insufficient cefadroxil of above-mentioned dosage form and preparation method thereof.
The present invention relates to a kind of cefadroxil oral cavity disintegration tablet, comprising the cefadroxil of effective dose and can be in the oral cavity rapidly disintegrate discharge the pharmaceutically acceptable excipient of medicine.
The cefadroxil oral cavity disintegration tablet contains principal agent cefadroxil, water-soluble filler, disintegrating agent, lubricant, also contains wetting agent or binding agent.
Various main materials and auxiliary materials weight shares prescription in the total amount shared ratio as follows:
A, principal agent 5～60%
B, water-soluble filler 10～70%
C, disintegrating agent 3～50%
F, lubricant 0.5～5%
E, wetting agent or binding agent 1～10%.
Water-soluble filler selects for use erythrose, mannitol, sorbitol, xylitol or other to help the material of moisture penetration in the pharmaceutical preparation, or the mixture of above two or more material.
Disintegrating agent is selected microcrystalline Cellulose (MCC), low-substituted hydroxypropyl cellulose (L-HPC), cross-linked carboxymethyl cellulose sodium (CCNa), polyvinylpolypyrrolidone (PVPP), crosslinked carboxymethylstach sodium (CCMS-Na) for use, or the mixture of above two or more material.
Can also contain gas-producing disintegrant in the above-mentioned disintegrating agent, as citric acid, tartaric acid, fumaric acid, sodium bicarbonate, sodium glycine carbonate, Glycine sodium fumarate.
Lubricant can be selected magnesium stearate, Pulvis Talci for use, or the two mixture.
The optional water of wetting agent, ethanol, or the mixture of the two.
Binding agent can be selected starch slurry, polyvidone or various cellulose family for use, or the mixture of above two or more material.
For covering the peculiar taste of cefadroxil, can also add the correctives that accounts for prescription gross weight 2～10% in the present invention, aspartame, cyclamate, saccharin sodium, Mentholum and various fruit powder essence etc. all can satisfy the requirement that improves cefadroxil oral cavity disintegration tablet mouthfeel.
This dosage form adopts wet granulation technology, can use conventional tablet pharmaceutical equipment production.
Concrete preparation method is as described below:
Take by weighing cefadroxil, water-soluble filler, correctives and part disintegrating agent by 100 mesh sieves; add an amount of wetting agent or binding agent granulation behind the mix homogeneously; with the disintegrating agent and the dried particles mix homogeneously of remainder, the qualified back of the inspection of semifinished product adds lubricant, and tabletting promptly behind the mixing.
The present invention runs in the oral cavity after the saliva rapidly that disintegrate becomes fine particle, and in order to investigate disintegrate effect of the present invention, we simulate oral environment and have formulated corresponding dissolve scattered time limit and molten shot degree algoscopy, and method is as follows:
The dissolve scattered time limit algoscopy is got this product a slice, put in the glass dish, getting the scale dropper measures 37 ℃ of water of 1ml and directly drips on unilateral, and the control rate of addition was finished timing simultaneously, inspection during to 45 seconds in 30 seconds, this product Ying Rong clears entirely, do not clear entirely as molten, get hard paper and scratch, hard core must not be arranged.
Molten shot degree algoscopy is got this product a slice, according to inspection technique disintegration (two appendix X of Chinese Pharmacopoeia version in 2000 A) lower device requirement, and hanging basket bottom screen cloth is replaced by 26 eye mesh screens, this product is put in the disintegration tester hanging basket, regulate the hanging basket height and make the bottom screen cloth concordant, and when this product contact water surface, pick up counting, in the time of 45 seconds with the water surface, mention the hanging basket inspection, should all pass through screen cloth.
According to said method the present invention and cefadroxil ordinary tablet are checked that the present invention all can moltenly loose in 45 seconds and by screen cloth, ordinary tablet is all defective, disintegration time of the present invention is significantly shorter than ordinary tablet, compares with ordinary tablet, and this dosage form has the following advantage:
The first, disintegrate is rapid, and is rapid-action.The present invention can be in 45 seconds in mouth disintegrate fast, make the rapid stripping of medicine, compare with cefadroxil conventional tablet or capsule, shortened dissolution time, accelerate its absorption, make medicine can bring into play the whole body therapeutic effect rapidly.
The second, intestinal is residual little, absorbs fully, and side effect is low.Cefadroxil has in various degree gastrointestinal reaction to some patient, as feel sick, vomiting.The present invention before reaching gastrointestinal tract rapidly disintegrate also be dispersed into trickle granule, medicine is extensively distributed in gastrointestinal tract, absorption point increases, and absorbs more fully, and has reduced medicine to the gastrointestinal local excitation.
The 3rd, medication is convenient.Cefadroxil need every day medication 2～3 times misses owing to reasons such as the inconvenience that is busy with one's work, fetches water may cause, thereby influences the antibacterial effect of medicine.The present invention needn't use water delivery service, saliva can make oral cavity disintegration tablet disintegrate or dissolving, both can resemble ordinary tablet swallows, can be placed in the water again and take after the disintegrate, also can need not to take medicine with water swallow, can take whenever and wherever possible, provide a great convenience condition, can guarantee that more medicine takes on time for the patient takes medicine.
The 4th, mouthfeel is good.Cefadroxil has a kind of special flavor of smelling, and makes us uncomfortable taste even the tablet of swallowing also can stay in mouth.The present invention has refrigerant Herba Menthae and fruit aroma and does not have obvious abnormal flavour after taste masking is handled, no sand type, and patient especially children taking compliance is good.
The generation of above-mentioned effect be because, it is described: water-soluble fillers such as erythrose and mannitol orally-dissolvable rapidly, cool taste is sweet and tasty, to thermally-stabilised, non-hygroscopic, can increase the hardness of tablet, very little to the disintegrate influence, be the desirable filler of oral cavity disintegration tablet; Microcrystalline Cellulose plays dual parts to fill and disintegrate in this test recipe, it has spongiform porous tubular structured, during pressurized, loose structure is by disorderly and unsystematic and become linear array, plastic deformation in addition, make it meet water after, hydrone enters tablet inside, destroy the hydrogen bond between the crystallite, impel disintegration of tablet; Low-substituted hydroxypropyl cellulose L-HPC has good hygroscopicity, meets water-soluble expanding and microcrystalline Cellulose when being used, and can play the disintegrate effect of the best.Citric acid contacts low amounts of water with sodium bicarbonate just can produce a large amount of bubbles, has helped the disintegrate of tablet more; Mentholum has the bad flavor of smelling that local anesthetic action can masking agents because of it, and cool taste, share as correctives to reach the flavoring effect with sweeting agents such as aspartame and essence.
The specific embodiment
Cefadroxil oral cavity disintegration tablet of the present invention contains principal agent, water-soluble filler, disintegrating agent, lubricant, also contains wetting agent or binding agent, the main materials and auxiliary materials weight share prescription in the total amount shared preferred proportion as follows:
A, principal agent 20～40%
B, water-soluble filler 20～50%
C, disintegrating agent 5～25%
F, lubricant 1～2%
E, wetting agent or binding agent 2～5%
Water-soluble filler is erythrose and mannitol preferably.
Disintegrating agent is microcrystalline Cellulose (MCC), low-substituted hydroxypropyl cellulose (L-HPC), citric acid and sodium bicarbonate preferably.
Wetting agent or binding agent be the second alcohol and water preferably.
Correctives is selected from aspartame, cyclamate, saccharin sodium, Mentholum and various fruit powder essence etc.
Correctives is aspartame, Mentholum and various fruit powder essence preferably.
With following embodiment the present invention is described.
Embodiment 1: the cefadroxil oral cavity disintegration tablet
| Component | Weight | Percentage by weight |
| Cefadroxil mannitol aspartame | 132g (being equivalent to cefadroxil anhydride 125g) 93g 1.5g | 44% (being equivalent to cefadroxil anhydride 41.7%) 31% 0.5% |
| Menthol sweet orange powdered flavor 5% PVP 95% ethanolic solution low-substituted hydroxypropyl cellulose microcrystalline cellulose tartaric acid sodium acid carbonate dolomol gross weight | An amount of 12g 48g of 1g 6g 1.5g 1.5g 3g 300g | 0.33% 4.55% an amount of 4% 16% 0.5% 0.5% 1% |
| Make 1000 altogether | ||
Concrete preparation method is as described below:
Take by weighing cefadroxil, mannitol, aspartame, Mentholum, Fructus Citri sinensis powdered flavor and part low-substituted hydroxypropyl cellulose by 100 mesh sieves; adding an amount of 5% polyvidone, 95% alcoholic solution behind the mix homogeneously granulates; low-substituted hydroxypropyl cellulose, tartaric acid and sodium bicarbonate and dried particles mix homogeneously with remainder; the qualified back of the inspection of semifinished product adds magnesium stearate, and tabletting promptly behind the mixing.
Embodiment 2: the cefadroxil oral cavity disintegration tablet
| Component | Weight | Percentage by weight |
| Cefadroxil erythrose aspartame Mentholum Fructus Citri sinensis powdered flavor 50% ethanol | 132g (being equivalent to cefadroxil anhydride 125g) 180g 2.5g 1g 12g is an amount of | 26.4% (being equivalent to cefadroxil anhydride 25%) 60% 0.5% 0.2% 2.4%, is an amount of |
| Sweet mellow wine powder low-substituted hydroxypropyl cellulose microcrystalline cellulose citric acid sodium acid carbonate dolomol gross weight | 60g 20g 80g 5g 2.5g 5g 500g | 12％ 4％ 16％ 1％ 0.5％ 1％ |
| Make 1000 altogether | ||
Concrete preparation method is as described below:
Take by weighing cefadroxil, erythrose, aspartame, Mentholum, Fructus Citri sinensis powdered flavor and part low-substituted hydroxypropyl cellulose by 100 mesh sieves; adding an amount of 50% alcoholic solution behind the mix homogeneously granulates; low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, citric acid and sodium bicarbonate and dried particles mix homogeneously with remainder; the qualified back of the inspection of semifinished product adds magnesium stearate, and tabletting promptly behind the mixing.
Embodiment 3: the cefadroxil oral cavity disintegration tablet
| Component | Weight | Percentage by weight |
| Cefadroxil erythrose Aspartame menthol sweet orange powdered flavor 50% ethanol PVPP microcrystalline cellulose citric acid | An amount of 40g 80g of 264g (being equivalent to cefadroxil anhydride 250g) 184g 3g 2g 12g 6g | 44% (being equivalent to cefadroxil anhydride 41.7%) 30.7% 0.5% 0.33% 2% an amount of 6.7% 13.3% 1% |
| Sodium bicarbonate magnesium stearate gross weight | 3g 6g 600g | 0.5％ 1％ |
| Make 1000 altogether | ||
Concrete preparation method is as described below:
Take by weighing cefadroxil, erythrose, aspartame, Mentholum, Fructus Citri sinensis powdered flavor and partial cross-linked polyvidone by 100 mesh sieves; add an amount of 50% alcohol granulation behind the mix homogeneously; polyvinylpolypyrrolidone, microcrystalline Cellulose, citric acid and sodium bicarbonate and dried particles mix homogeneously with remainder; the qualified back of the inspection of semifinished product adds magnesium stearate, and tabletting promptly behind the mixing.
Embodiment 4: the cefadroxil oral cavity disintegration tablet
| Component | Weight | Percentage by weight |
| Cefadroxil erythrose Aspartame menthol sweet orange powdered flavor 50% ethanol Ac-Di-Sol microcrystalline cellulose citric acid sodium acid carbonate magnesium stearate talc gross weight is made 1000 altogether | An amount of 30g 80g of 264g (being equivalent to cefadroxil anhydride 250g) 191g 3g 2g 12g 6g 3g 3g 6g 600g | 44% (being equivalent to cefadroxil anhydride 41.7%) 31.8% 0.5% 0.33% 2% an amount of 5% 13.3% 1% 0.5% 0.5% 1% |
Concrete preparation method is as described below:
Take by weighing cefadroxil, erythrose, aspartame, Mentholum, Fructus Citri sinensis powdered flavor and partial cross-linked sodium carboxymethyl cellulose by 100 mesh sieves; add an amount of 50% alcohol granulation behind the mix homogeneously; cross-linking sodium carboxymethyl cellulose, microcrystalline Cellulose, citric acid and sodium bicarbonate and dried particles mix homogeneously with remainder; the qualified back of the inspection of semifinished product adds magnesium stearate and Pulvis Talci, and tabletting promptly behind the mixing.
Claims (6)
1, a kind of cefadroxil oral cavity disintegration tablet is characterized in that being made by the main materials and auxiliary materials of following weight percentage: cefadroxil 26.4%, erythrose 60%, aspartame 0.5%, Mentholum 0.2%, Fructus Citri sinensis powdered flavor 2.4%, 50% ethanol are an amount of, mannitol powder 12%, low-substituted hydroxypropyl cellulose 4%, microcrystalline Cellulose 16%, citric acid 1%, sodium bicarbonate 0.5%, magnesium stearate 1%.
2, a kind of cefadroxil oral cavity disintegration tablet is characterized in that being made by the main materials and auxiliary materials of following weight percentage: cefadroxil 44%, erythrose 30.7%, aspartame 0.5%, Mentholum 0.33%, Fructus Citri sinensis powdered flavor 2%, 50% ethanol are an amount of, polyvinylpolypyrrolidone 6.7%, microcrystalline Cellulose 13.3%, citric acid 1%, sodium bicarbonate 0.5%, magnesium stearate 1%.
3, a kind of cefadroxil oral cavity disintegration tablet is characterized in that being made by the main materials and auxiliary materials of following weight percentage: cefadroxil 44%, erythrose 31.8%, aspartame 0.5%, Mentholum 0.33%, Fructus Citri sinensis powdered flavor 2%, 50% ethanol are an amount of, cross-linking sodium carboxymethyl cellulose 5%, microcrystalline Cellulose 13.3%, citric acid 1%, sodium bicarbonate 0.5%, magnesium stearate 0.5%, Pulvis Talci 1%.
4, cefadroxil oral cavity disintegration tablet according to claim 1; its preparation method is: take by weighing cefadroxil, erythrose, aspartame, Mentholum, Fructus Citri sinensis powdered flavor and part low-substituted hydroxypropyl cellulose by 100 mesh sieves; adding an amount of 50% alcoholic solution behind the mix homogeneously granulates; low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, citric acid and sodium bicarbonate and dried particles mix homogeneously with remainder; the qualified back of the inspection of semifinished product adds magnesium stearate, and tabletting promptly behind the mixing.
5, cefadroxil oral cavity disintegration tablet according to claim 2; its preparation method is: take by weighing cefadroxil, erythrose, aspartame, Mentholum, Fructus Citri sinensis powdered flavor and partial cross-linked polyvidone by 100 mesh sieves; add an amount of 50% alcohol granulation behind the mix homogeneously; polyvinylpolypyrrolidone, microcrystalline Cellulose, citric acid and sodium bicarbonate and dried particles mix homogeneously with remainder; the qualified back of the inspection of semifinished product adds magnesium stearate, and tabletting promptly behind the mixing.
6, cefadroxil oral cavity disintegration tablet according to claim 3; its preparation method is: take by weighing cefadroxil, erythrose, aspartame, Mentholum, Fructus Citri sinensis powdered flavor and partial cross-linked sodium carboxymethyl cellulose by 100 mesh sieves; add an amount of 50% alcohol granulation behind the mix homogeneously; cross-linking sodium carboxymethyl cellulose, microcrystalline Cellulose, citric acid and sodium bicarbonate and dried particles mix homogeneously with remainder; the qualified back of the inspection of semifinished product adds magnesium stearate and Pulvis Talci, and tabletting promptly behind the mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100075451A CN1311830C (en) | 2004-02-27 | 2004-02-27 | Cefadroxil oral disintegrant tablet, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100075451A CN1311830C (en) | 2004-02-27 | 2004-02-27 | Cefadroxil oral disintegrant tablet, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1618428A CN1618428A (en) | 2005-05-25 |
| CN1311830C true CN1311830C (en) | 2007-04-25 |
Family
ID=34763050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100075451A Expired - Lifetime CN1311830C (en) | 2004-02-27 | 2004-02-27 | Cefadroxil oral disintegrant tablet, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1311830C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546755A (en) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | Cefadroxil composition freeze-drying tablet and preparation method thereof |
| CN104800177B (en) * | 2015-05-12 | 2018-01-16 | 湖南科伦制药有限公司 | A kind of Cefadroxil tablets and preparation method thereof |
| CN109776573A (en) * | 2018-08-16 | 2019-05-21 | 上海金城药业有限公司 | Cefadroxil preparation treats the new indication of female reproductive system infection |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88101895A (en) * | 1987-04-24 | 1988-11-30 | 里法尔公司 | Novel crystallisation of cefadroxil and preparation method thereof |
| CN88100566A (en) * | 1987-06-17 | 1988-12-28 | 里法尔公司 | Substantially anhydrous crystalline cefadroxil and process for its preparation |
| CN1031085A (en) * | 1987-08-03 | 1989-02-15 | 里法尔公司 | The method for preparing crystalline cefadroxil monoltyrate |
| US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
-
2004
- 2004-02-27 CN CNB2004100075451A patent/CN1311830C/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88101895A (en) * | 1987-04-24 | 1988-11-30 | 里法尔公司 | Novel crystallisation of cefadroxil and preparation method thereof |
| CN88100566A (en) * | 1987-06-17 | 1988-12-28 | 里法尔公司 | Substantially anhydrous crystalline cefadroxil and process for its preparation |
| CN1031085A (en) * | 1987-08-03 | 1989-02-15 | 里法尔公司 | The method for preparing crystalline cefadroxil monoltyrate |
| US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1618428A (en) | 2005-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2393640T3 (en) | Orodisintegrable tablets | |
| CN101904824B (en) | Olanzapine orally-disintegrating tablet preparation and preparation method thereof | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| CN100588400C (en) | Fast disintegrant containing paroxetine | |
| CN101143135B (en) | Melatonin orally disintegrating tablet and preparation method thereof | |
| CN101209249A (en) | Spaston orally disintegrating tablets and preparation thereof | |
| JP7036856B2 (en) | Orally disintegrating tablet | |
| CN107095853A (en) | A kind of oral disnitegration tablet disintegrant combination and its application method | |
| CN101461788B (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN101401795A (en) | Imatinib mesylate orally disintegrating tablets and preparation method thereof | |
| Siraj et al. | Formulation and evaluation of oral fast dissolving tablet of ondansetron hydrochloride by coprocess excipients | |
| CN101904827A (en) | Orally disintegrating tablet of ambroxol hydrochloride and preparation method thereof | |
| CN101284011B (en) | Oleanolic acid orally disintegrating tablet and preparation method thereof | |
| CN101361720A (en) | Nebivolol hydrochloric acid orally disintegrating tablet and preparation method thereof | |
| CN101444513B (en) | Cefaclor orally disintegrating tablet and preparation method thereof | |
| CN1311830C (en) | Cefadroxil oral disintegrant tablet, and its prepn. method | |
| CN102440973A (en) | Diphenhydramine citrate orally disintegrating tablet and preparation method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN102499907A (en) | Orally disintegrating tablet composition | |
| CN100490816C (en) | Azithromycin oral disintegration tablet and its preparing method | |
| CN102048705B (en) | Palonosetron hydrochloride orally disintegrating tablet and preparation method thereof | |
| US20190083628A1 (en) | Pharmaceutical composition particles and orally disintegrating preparation including the same | |
| EP3421032A1 (en) | Pharmaceutical composition particles, orally disintegrating preparation including same, and method for producing pharmaceutical composition particles | |
| CN100387226C (en) | Cepharanthine oral disintegration tablet and its preparing method | |
| CN100417392C (en) | An effervescence tablet of cold-treating preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070425 |